The goal of this project is to explore the biological mechanisms that lie behind these differences in drug response. AML is a disease of the immune cells in our blood, and therefore we want to better understand the role that immune signalling plays in cancer treatment at the cellular level. We have chosen to analyse the activity of a set of transcription factors that lie at the heart of many signalling cascades, and drive the expression of genes that drive cancer growth and drug resistance. We will analyse patterns of transcription factor activity across the 34 AML patients, and see how this correlates with treatment response. We are also developing a high-content imaging assay that will allow us to measure the activation of these proteins at a single-cell level, and identify compounds that can positively influence their behaviour.